Brief: Arbutus Doses First Patient In Additional Treatment Arm Of Phase 2a Triple Combination Clinical Trial That Includes A PD-1 Monoclonal Antibody

Arbutus Biopharma

21/06/2023 12:33

June 21 (Reuters) - Arbutus Biopharma Corp  ABUS.O :
    * ARBUTUS DOSES FIRST PATIENT IN ADDITIONAL TREATMENT ARM OF
PHASE
2A TRIPLE COMBINATION CLINICAL TRIAL THAT INCLUDES A PD-1
MONOCLONAL ANTIBODY
    * ARBUTUS BIOPHARMA - PRELIMINARY DATA FROM ORIGINAL PORTION
OF
TRIAL IS EXPECTED IN SECOND HALF OF 2023

Source text for Eikon:  ID:nGNXbTSV2D 
Further company coverage:  ABUS.O 

 ((reuters.briefs@thomsonreuters.com;))